The Texas Lung Cancer Conference 2026 took place from April 9 to 11 at ACL Live at The Moody Theater in Austin, Texas, bringing together leading voices in thoracic oncology for three days of scientific exchange and multidisciplinary discussion. Chaired by Dr. Tina Cascone and Dr. Stephen Liu, the meeting convened more than 100 experts to examine current developments in lung cancer research, clinical practice, and emerging therapeutic strategies.
The conference program began on Thursday evening, April 9, with a Welcome Reception and poster competition, setting the tone for broader academic engagement throughout the meeting. At a time when thoracic oncology was continuing to evolve rapidly, the Texas Lung Cancer Conference served as an important forum for reviewing new evidence, sharing expert perspectives, and strengthening collaboration across the lung cancer community.
Here are 20 insightful posts you shouldn’t miss from leading experts highlighting key perspectives, research updates, and important discussions shared during the Texas Lung Cancer Conference 2026.
20 Posts Not To Miss From Texas Lung Cancer Conference
“The fourth annual Texas Lung Cancer Conference LIVE from ACL was fabulous! Thank you to Dr. Stephen Liu & Dr. Tina Cascone for the invitation and the wonderful IDEOlogy Health™ team as such fantastic hosts! Grateful for a thoracic oncology community that is TRULY family!”
“Today was the first time I observed Salma Jabbour in a debate. It wouldn’t have mattered who was on the other side as she was absolutely spectacular using data and logic to clarify CRT is often the better local therapy for bulky T4N2 NSCLC.”
“Texas lung cancer day 2: What is the role of radiotherapy vs. surgery in stage III NSCLC in the era of IO? In the debate about RT Salma Jabbour vs. surgery Brendon Stiles, RT won in the case of T4 N2M0 NSCLC. Representatives from RT and Surgery did a great job inspiring lung cancer colleagues about optimizing local TX with novel systemic TX. Ultimately, we need to answer the question of what we can/should offer to our patients, including our family members. Congratulations on a very successful IASLC.”
“Arrived at Texas Lung 26 bumping into absolute rockstars in thoracic oncology. Pinch me-being in the same room with people who are changing the story of lung cancer every day. Grateful to be here. Let’s go! ”
“Kicking off day 2 Texas Lung 26: Iyengar Puneeth shows outstanding questions in SCLC: What is a role of PCI now in limited stage? Should we still use consolidation RT in extensive disease?”
“EGFR+ NSCLC to SCLC: what to do today? 1. Prioritize clinical trial 2. If no trial, chemo + TKI 3. Tarlatamab not the “blockbuster” solution for most pts but DLL3 expression might help us.”
“Texas Lung 26 Hold ‘Em Debate.”
“From EGFR to ALK to RET, adjuvant therapy in lung cancer is evolving fast. ADAURA, ALINA, and LIBRETTO-432 are redefining what “curative intent” can look like after surgery. The question is no longer if we should treat, but who, when, and how long.”
“Another memorable Texas Lung debate: T4N2 NSCLC: periop chemoIO approach vs. chemoRT→IO. Dr. Salma Jabbour takes the trophy home. Both Drs. Brendon Stiles & Jabbour made a strong case and agreed that multi-D discussion & shared decision-making with patients remain key.”
“Lung cancer- be warned! This is the thoracic team searching for you day and night to protect our patients in Da Bronx!”
“Transformed small cell… best practices below by Dr Carl Gay 1L platinum etop + osi 2L if DLL3 greater than 50% consider tarla + tki, if less , consider lurbi osi Most important message – consider a trial here! This space is in dire need of support !”
” Thank you to Dr. Tina Cascone and Stephen Liu
for bringing together experts in thoracic oncology with the shared goal of innovative, patient-centered care at the 2026. It was a privilege to share my work as a poster competition winner!”
“More like Brendon “Styles” Brendon Stiles , Texas Lung Hold ‘Em Debate: Surgical vs Non-surgical Approaches to Early-Stage Lung Cancer”
“Had a fantastic experience at Texas Lung 26. Honored to present my research and learn from leaders advancing lung cancer care for our patients. Sincere thanks to Rami Manochakian for the invaluable mentorship, and to Stephen Liu and Tina Cascone for curating an outstanding meeting.”
“MPM26 Lung cancer advocacy in action at the 3rd Biennial Miami Precision Medicine Conference- lung cancer survivors are a living proof of why research matters precision oncology biomaker testing in cancer ”
“Some amazing posters from such talented trainees and junior faculty at the Welcome Poster Reception for Texas Lung 26! Day 1 of TLC conference is tomorrow at acl live! ”
“Congratulations to Stephen Liu & Tina Cascone on a very successful Texas Lung 26. Raising the bar every single year.”
“High quality study from Benjamin Besse showing only 26% of pts need retreatment after getting 2 yrs pembro for NSCLC. However, outcome for IO rechallenge was mixed, w/ many pts clearly not responding and dying. Much like CM-153 & w/ prior pooled report of Abreu-Rodriguez showing only 19-27% ORR with pembro re-challenge. So still an unresolved question: whether 2-yr discontinuation is optimal for all patients? ”
“I have SO much respect for Dr. Stephen Liu . Not only is he an amazing clinician who is deeply compassionate, but he is truly one of the very BEST communicators in our field. And that matters now more than ever. Grateful for all you do and for the invite Texas Lung 26.”
“The 4th annual Texas Lung Cancer Conference TLCconference Texas Lung 26 kicks off in just over day! TBH: One of the BEST high-impact conferences you will ever attend, plus it’s held at the Moody Theater! Hosted by co-chairs Stephen Liu & Tina Cascone, and supported by the stellar team at IDEOlogy Health. Texas Lung Hold ‘Em Debate Dealer Joshua Sabari, Brendon Stiles vs. Salma Jabbour. ”
Explore more oncology news and features on OncoDaily.
Written by Nare Hovhannisyan,MD